Overview
News
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$21.5M
3 rounds on record
Latest round
$12M
Seed · Feb 2024 · 2 yr ago
Team
6
US Form 5500 (plan participants) · Dec 2025 · 0% in a year
Revenue
$25M
2022 · SEC Form D 0001969222-23-000001
Backers
2
Playground, venBio Partners
The money's age
Long since its last round
31 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 26, 2024 Launched Insamo launches to develop cyclic peptides · Chemical & Engineering News Feb 25, 2024 Raised a round Seed $12M · Pulse 2.0 Mar 8, 2023 Raised a round Venture round $9.5M · SEC Form D 2022 Founded
Funding rounds
RoundDateAmountInvestorsSource
Seed Feb 2024 $12M — Pulse 2.0
Debt Financing Dec 2023 $2.3M — SEC Form D
Venture round Mar 2023 $9.5M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity INSAMO INC. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Timothy CravenExecutive Officer, DirectorSEC Form D
Toby PassiouraExecutive Officer, DirectorSEC Form D
Glen McintyreExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Similar startupsby what they do, their industry and backers
AqemiaVenture round $38M · 21 mo ago • Founded 2019 • 51-200 employees
Aqemia is a Paris company founded in 2019 that designs drug candidates with quantum-inspired statistical physics and deep learning. Its…
immunitoAIVenture round $6.1M · 10 mo ago • Founded 2020 • 11-50 employees • 1 role
immunitoAI is an AI-driven biotechnology company accelerating antibody discovery and the development of antibody-based therapies through…
KisoJi Biotechnology. Breakthrough antibody discovery forbreakthrough therapeutics.
Medium BiosciencesVenture round $31M · 4 yr ago • 51-200 employees
Custom affinity reagents, designed for your target and application. Medium Biosciences designs experimentally validated affinity reagents…
Advanced Antibody Design Services. Macromoltek harnesses the power of computational modeling and artificial intelligence to accelerate and…
PlantingSpaceFounded 2021 • 11-50 employees • 4 roles
We are building a system which accurately represents knowledge and uncertainty, to enable the discovery of insights and transparent problem…

Overview

Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding affinity.

News

News CHOSUNBIZ 9 months ago
Jung Jun-ha stuns fans with surprise 'Insamo' reunion stage on Hangout With Yoo
Jung Jun-ha stuns fans with surprise Insamo reunion stage on Hangout With Yoo Hangout With Yoo moved everyone with the Insamo gathering of unpopular
Read more
Report
News Sports Kyunghyang 9 months ago
Yoo Jae-suk, surprised by 'Insamo' fan devotion…
Members of 'Insamo (Association of Unpopular People)' finally come face to face with their hidden fans. On the December 27 broadcast of MBC variety show 'How Do You Play?' (directed by Kim Jin-yong...
Read more
Report
News Nature Index 1 year ago
Insamo South Pty Ltd,
The Nature Index tracks the affiliations of scientific articles from high-quality publications. The research profile for Insamo South Pty Ltd, reflects the research output of authors from Insamo South Pty Ltd, who published articles in the 145 journals in
Read more
Report
News Chemical & Engineering News 2 years ago
Insamo launches to develop cyclic peptides
Chemical & Engineering News (C&EN): Keeping you up to date with the chemistry news that matters most. Published by the American Chemical Society.
Read more
Report
Pro access
Upgrade to see all 10 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.

People

Timothy Craven
Executive Officer, Director
Toby Passioura
Executive Officer, Director
Glen Mcintyre
Executive Officer, Director
Corey Goodman
Director
Matt Hershenson
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Berkeley United States
HQ
50-200 est. staff

Financials

Est. Annual Revenue
$15M
2022
Total raised
$23.8M
Latest round
Seed
Funding rounds
3
Funding rounds
Round Announced Amount
Seed 2024 $12M Details
Debt Financing 2023 $2.3M Details
Venture - Series Unknown 2023 $9.5M Details